InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: None

Tuesday, 08/04/2020 8:35:38 AM

Tuesday, August 04, 2020 8:35:38 AM

Post# of 403018
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing


Brilacidin is showing consistent and robust antiviral activity across the viral lifecycle in human lung and Vero cells; potential as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected
Article to be submitted for peer-review publication in September, with pre-print made available

WAKEFIELD, MA – August 4, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving an update from a U.S. Regional Biocontainment Laboratory (RBL) based on ongoing in vitro testing supporting Brilacidin as a treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.

A new experiment in a human lung epithelial cell line with the live (or wild type) virus showed that Brilacidin inhibited SARS-CoV-2 when administered post-infection. These results complement earlier RBL experiments in the same lung cell line that showed Brilacidin, when directly incubated with the live virus, exhibited potent inhibition. As Brilacidin is showing consistent and robust anti-SARS-CoV-2 activity across the viral lifecycle, the Company believes the drug could be used as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected.

At the RBL, ongoing direct inhibition experiments are being conducted with the live virus, including experiments to determine the Selectivity Index—a ratio that compares a drug’s cytotoxicity and antiviral activity—of Brilacidin in human lung cells and also in Vero cells. New in vitro neutralization experiments (with a pseudotyped virus) and binding experiments (using isolated SARS-CoV-2 Spike protein) are helping to further elucidate Brilacidin’s antiviral mechanisms against SARS-CoV-2. The richness of the growing RBL data is informing our planned Phase 2 clinical trial of Brilacidin for COVID-19. Upon completion of in vitro testing at the RBL, an academic paper is anticipated to be submitted in September for peer-review publication, with a pre-print to be made available at that time.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News